Well Referenced

Tag: visual acuity

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration

This 2020 study evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 32 eyes from patients aged 69–90 with dry age-related macular degeneration (AMD). BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After treatment, 63% of eyes showed improvement in visual acuity, 34%

Read More »
June 26, 2025 No Comments

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease

The SCOTS and SCOTS2 trials evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 34 eyes from patients with Stargardt Disease. BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After one year, 61.8% of eyes showed visual improvement, 23.5% remained stable, and 14.7%

Read More »
June 26, 2025 No Comments

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Leber’s Hereditary Optic Neuropathy

This study reports on the SCOTS trial, which utilized autologous bone marrow-derived stem cells (BMSCs) to treat patients with Leber’s Hereditary Optic Neuropathy (LHON). Treatment methods included retrobulbar, subtenon, intravitreal, intra-optic nerve, subretinal, and intravenous injections of BMSCs. Patients experienced visual acuity improvements, with gains up to 35 letters on

Read More »
June 26, 2025 No Comments

Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium in Patients with Age-Related Macular Degeneration and Stargardt’s Macular Dystrophy: Follow-Up of Two Open-Label Phase 1/2 Studies

This study reports on two open-label Phase 1/2 trials assessing the safety and tolerability of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) in nine patients with atrophic age-related macular degeneration (AMD) and nine with Stargardt’s macular dystrophy. Patients received varying doses (50,000 to 150,000 cells) and

Read More »
June 26, 2025 No Comments

A Phase I Clinical Trial of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells for Early-Stage Stargardt Macular Degeneration: 5-Years’ Follow-Up

This Phase I clinical trial evaluated the long-term safety and efficacy of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells in seven patients with early-stage Stargardt macular degeneration (STGD1). Each patient received a single subretinal injection of 1 × 10⁵ hESC-RPE cells in one eye, with

Read More »
June 26, 2025 No Comments

A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy

This 2011 multicenter, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of idebenone (900 mg/day) over 24 weeks in 85 patients with Leber’s hereditary optic neuropathy (LHON) carrying the m.3460G>A, m.11778G>A, or m.14484T>C mitochondrial DNA mutations. The primary endpoint—best recovery in visual acuity—did not reach statistical significance in the

Read More »
June 26, 2025 No Comments

Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study

This randomized controlled trial evaluated the efficacy of major ozonated autohemotherapy (O3-AHT) in treating dry age-related macular degeneration (AMD). The study showed that O3-AHT significantly improved visual acuity, with 25% of patients in the treatment group gaining at least one line of vision after 12 months, compared to none in

Read More »
June 26, 2025 No Comments